Drugs / Varespladib Methyl
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01359605 | Jun → Jul 2011 | — | Anthera Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01359579 | Jun 2011 → Apr 2012 | impaired renal function disease | Anthera Pharmaceuticals | Terminated | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05717062 | May 2023 → Nov 2024 | snakebite envenomation | Ophirex, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04996264 | Aug 2021 → Jun 2023 | snakebite envenomation | Ophirex, Inc. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00743925 Comparator | Jul 2008 → Jan 2010 | acute coronary syndrome | Anthera Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Varespladib-methyl | “Varespladib-methyl (LY333013) is an IR, oval, white, film-coated tablet at a dosage strength of 250 mg for oral administration.” NCT04996264 ↗ |
| Known as | LY-333013 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105659 ↗ |
| Known as | S-3013 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105659 ↗ |
| Known as | Varespladib methyl ester | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105659 ↗ |
| Action | Inhibit | “sPLA(2) inhibition with varespladib 500 mg daily versus placebo” PMID 20863951 ↗ Sep 20103“Group X secretory phospholipase A2 inhibitor” CHEMBL2105659 ↗ “Phospholipase A2 group IIA inhibitor” CHEMBL2105659 ↗ “Phospholipase A2 group V inhibitor” CHEMBL2105659 ↗ |
| Modality | Small molecule | “the small-molecule drug varespladib-methyl” NCT04996264 ↗ |
| Route | Oral | “2 Tablets (250 mg each) once daily for at least 24 weeks” NCT00743925 ↗ |
| Target | PLA2G10 | “Group X secretory phospholipase A2 inhibitor” CHEMBL2105659 ↗ |
| Target | PLA2G2A | “Phospholipase A2 group IIA inhibitor” CHEMBL2105659 ↗ |
| Target | PLA2G5 | “Phospholipase A2 group V inhibitor” CHEMBL2105659 ↗ |